Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 5368 | 8.075 |
09:34 ET | 200 | 8.15 |
09:36 ET | 1038 | 8.11 |
09:38 ET | 400 | 8.1129 |
09:39 ET | 461 | 8.18 |
09:41 ET | 5358 | 8.16 |
09:43 ET | 100 | 8.18 |
09:45 ET | 5212 | 8.1607 |
09:48 ET | 600 | 8.16 |
09:50 ET | 1659 | 8.2 |
09:52 ET | 2210 | 8.19 |
09:54 ET | 11233 | 8.24 |
09:56 ET | 2388 | 8.245 |
09:57 ET | 5228 | 8.29 |
09:59 ET | 2180 | 8.235 |
10:01 ET | 447 | 8.2102 |
10:03 ET | 2200 | 8.175 |
10:06 ET | 10253 | 8.115 |
10:08 ET | 2985 | 8.1616 |
10:10 ET | 301 | 8.165 |
10:14 ET | 774 | 8.1 |
10:15 ET | 1256 | 8.13 |
10:17 ET | 2708 | 8.125 |
10:19 ET | 1100 | 8.07 |
10:21 ET | 2010 | 8.04 |
10:24 ET | 8913 | 8.02 |
10:26 ET | 186 | 8.0371 |
10:28 ET | 748 | 8.02 |
10:30 ET | 1686 | 8.15 |
10:33 ET | 826 | 8.05 |
10:35 ET | 285 | 8.04 |
10:37 ET | 100 | 7.99 |
10:42 ET | 500 | 8.05 |
10:44 ET | 500 | 8.04 |
10:50 ET | 200 | 8.06 |
10:51 ET | 131 | 8.0747 |
10:55 ET | 800 | 8.05 |
10:57 ET | 300 | 8.04 |
11:00 ET | 1440 | 8.06 |
11:04 ET | 2300 | 8.08 |
11:06 ET | 520 | 8.1 |
11:09 ET | 200 | 8.13 |
11:11 ET | 2351 | 8.114 |
11:13 ET | 390 | 8.14 |
11:15 ET | 100 | 8.14 |
11:18 ET | 200 | 8.125 |
11:20 ET | 100 | 8.1 |
11:22 ET | 2225 | 8.175 |
11:24 ET | 4277 | 8.16 |
11:26 ET | 1076 | 8.16 |
11:27 ET | 7614 | 8.2 |
11:31 ET | 1725 | 8.29 |
11:33 ET | 368 | 8.35 |
11:38 ET | 3462 | 8.3799 |
11:40 ET | 2300 | 8.35 |
11:42 ET | 1100 | 8.4 |
11:44 ET | 839 | 8.41 |
11:45 ET | 600 | 8.405 |
11:47 ET | 722 | 8.4199 |
11:49 ET | 200 | 8.41 |
11:51 ET | 1498 | 8.35 |
11:54 ET | 200 | 8.375 |
11:56 ET | 600 | 8.35 |
11:58 ET | 1325 | 8.31 |
12:00 ET | 2789 | 8.306789 |
12:02 ET | 632 | 8.25 |
12:05 ET | 863 | 8.27 |
12:07 ET | 500 | 8.27 |
12:09 ET | 722 | 8.27 |
12:12 ET | 708 | 8.22 |
12:18 ET | 400 | 8.22 |
12:20 ET | 400 | 8.2 |
12:21 ET | 509 | 8.1964 |
12:23 ET | 712 | 8.16 |
12:25 ET | 400 | 8.13 |
12:27 ET | 1607 | 8.134 |
12:30 ET | 600 | 8.13 |
12:32 ET | 1075 | 8.16 |
12:34 ET | 4274 | 8.21 |
12:38 ET | 3949 | 8.23 |
12:41 ET | 881 | 8.23 |
12:45 ET | 700 | 8.19 |
12:48 ET | 2357 | 8.1901 |
12:50 ET | 704 | 8.19 |
12:52 ET | 2998 | 8.15 |
12:54 ET | 5893 | 8.09 |
12:56 ET | 4600 | 8.14 |
12:57 ET | 200 | 8.16 |
12:59 ET | 304 | 8.11 |
01:01 ET | 424 | 8.14 |
01:03 ET | 1273 | 8.145 |
01:06 ET | 200 | 8.18 |
01:08 ET | 2400 | 8.16 |
01:10 ET | 300 | 8.14 |
01:12 ET | 300 | 8.13 |
01:14 ET | 723 | 8.15 |
01:21 ET | 501 | 8.195 |
01:24 ET | 100 | 8.19 |
01:26 ET | 200 | 8.21 |
01:28 ET | 2206 | 8.215 |
01:32 ET | 100 | 8.18 |
01:33 ET | 100 | 8.165 |
01:35 ET | 600 | 8.15 |
01:37 ET | 230 | 8.16 |
01:42 ET | 400 | 8.14 |
01:44 ET | 1264 | 8.155 |
01:46 ET | 586 | 8.16 |
01:48 ET | 257 | 8.14 |
01:50 ET | 306 | 8.195 |
01:53 ET | 500 | 8.21 |
01:55 ET | 100 | 8.205 |
01:57 ET | 100 | 8.205 |
02:02 ET | 800 | 8.195 |
02:04 ET | 190 | 8.22 |
02:06 ET | 1300 | 8.225 |
02:08 ET | 1512 | 8.22 |
02:09 ET | 322 | 8.21 |
02:11 ET | 630 | 8.214 |
02:13 ET | 300 | 8.19 |
02:18 ET | 200 | 8.18 |
02:20 ET | 400 | 8.17 |
02:24 ET | 290 | 8.19 |
02:29 ET | 1300 | 8.16 |
02:31 ET | 200 | 8.14 |
02:33 ET | 100 | 8.16 |
02:38 ET | 446 | 8.17 |
02:40 ET | 375 | 8.18 |
02:44 ET | 590 | 8.19 |
02:45 ET | 18492 | 8.19 |
02:47 ET | 2950 | 8.2 |
02:49 ET | 2823 | 8.17 |
02:51 ET | 500 | 8.17 |
02:54 ET | 1006 | 8.15 |
02:56 ET | 999 | 8.16 |
02:58 ET | 1514 | 8.18 |
03:00 ET | 100 | 8.17 |
03:03 ET | 400 | 8.21 |
03:05 ET | 1247 | 8.2 |
03:07 ET | 464 | 8.19 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 289.0M | -2.1x | --- |
Solid Biosciences Inc | 290.6M | -2.3x | --- |
PepGen Inc | 295.6M | -2.7x | --- |
Kyverna Therapeutics Inc | 297.3M | 0.0x | --- |
enGene Holdings Inc | 300.2M | -1.4x | --- |
Tectonic Therapeutic Inc | 272.1M | -1.0x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $289.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.50 |
EPS | $-3.90 |
Book Value | $4.72 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.